Literature DB >> 18199646

Complement is an essential component of the immune response to adeno-associated virus vectors.

Anne K Zaiss1, Matthew J Cotter, Lindsay R White, Sharon A Clark, Norman C W Wong, V Michael Holers, Jeffrey S Bartlett, Daniel A Muruve.   

Abstract

Adeno-associated virus (AAV) vectors are associated with relatively mild host immune responses in vivo. Although AAV induces very weak innate immune responses, neutralizing antibodies against the vector capsid and transgene still occur. To understand further the basis of the antiviral immune response to AAV vectors, studies were performed to characterize AAV interactions with macrophages. Primary mouse macrophages and human THP-1 cells transduced in vitro using an AAV serotype 2 (AAV2) vector encoding green fluorescent protein did not result in measurable transgene expression. An assessment of internalized vector genomes showed that AAV2 vector uptake was enhanced in the presence of normal but not heat-inactivated or C3-depleted mouse/human serum. Enhanced uptake in the presence of serum coincided with increased macrophage activation as determined by the expression of NF-kappaB-dependent genes such as macrophage inflammatory protein 2 (MIP-2), interleukin-1beta (IL-1beta), IL-8, and MIP-1beta. AAV vector serotypes 1 and 8 also activated human and mouse macrophages in a serum-dependent manner. Immunoprecipitation studies demonstrated the binding of iC3b complement protein to the AAV2 capsid in human serum. AAV2 did not activate the alternative pathway of the complement cascade and lacked cofactor activity for factor I-mediated degradation of C3b to iC3b. Instead, our results suggest that the AAV capsid also binds complement regulatory protein factor H. In vivo, complement receptor 1/2- and C3-deficient mice displayed impaired humoral immunity against AAV2 vectors, with a delay in antibody development and significantly lower neutralizing antibody titers. These results show that the complement system is an essential component of the host immune response to AAV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199646      PMCID: PMC2259003          DOI: 10.1128/JVI.01990-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

Review 1.  Structure and biology of complement protein C3, a connecting link between innate and acquired immunity.

Authors:  A Sahu; J D Lambris
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

Review 2.  Structure-function relationships of complement receptor type 1.

Authors:  M Krych-Goldberg; J P Atkinson
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

3.  Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria.

Authors:  U Fagiolo; F Kricek; C Ruf; A Peserico; A Amadori; M Cancian
Journal:  J Allergy Clin Immunol       Date:  2000-09       Impact factor: 10.793

Review 4.  Regulation of humoral immune responses by CD21/CD35.

Authors:  Z Chen; S B Koralov; G Kelsoe
Journal:  Immunol Rev       Date:  2000-08       Impact factor: 12.988

5.  Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression.

Authors:  K Qing; J Hansen; K A Weigel-Kelley; M Tan; S Zhou; A Srivastava
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection.

Authors:  Manfred Kopf; Brian Abel; Awen Gallimore; Michael Carroll; Martin F Bachmann
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

Review 7.  Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein.

Authors:  G D Ross
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

8.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Identification of the streptococcal M protein binding site on membrane cofactor protein (CD46).

Authors:  Eleni Giannakis; T Sakari Jokiranta; Rebecca J Ormsby; Thomas G Duthy; Dean A Male; Dale Christiansen; Vince A Fischetti; Chris Bagley; Bruce E Loveland; David L Gordon
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

10.  Complement activation by recombinant adenoviruses.

Authors:  G Cichon; S Boeckh-Herwig; H H Schmidt; E Wehnes; T Müller; P Pring-Akerblom; R Burger
Journal:  Gene Ther       Date:  2001-12       Impact factor: 5.250

View more
  50 in total

1.  Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

Authors:  Jie Tian; Zhili Xu; Jeffrey S Smith; Sean E Hofherr; Michael A Barry; Andrew P Byrnes
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

2.  Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement.

Authors:  Zhili Xu; Jie Tian; Jeffrey S Smith; Andrew P Byrnes
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

3.  Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery.

Authors:  Daniel Stone; Ying Liu; Zong-Yi Li; Robert Strauss; Eric E Finn; James M Allen; Jeffrey S Chamberlain; André Lieber
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

4.  The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.

Authors:  Ashley T Martino; Masataka Suzuki; David M Markusic; Irene Zolotukhin; Renee C Ryals; Babak Moghimi; Hildegund C J Ertl; Daniel A Muruve; Brendan Lee; Roland W Herzog
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

5.  Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle.

Authors:  Alice Toromanoff; Oumeya Adjali; Thibaut Larcher; Marcelo Hill; Lydie Guigand; Pierre Chenuaud; Jack-Yves Deschamps; Olivier Gauthier; Gilles Blancho; Bernard Vanhove; Fabienne Rolling; Yan Chérel; Philippe Moullier; Ignacio Anegon; Caroline Le Guiner
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

Review 6.  Gene therapy for heart failure.

Authors:  Lisa Tilemann; Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2012-03-02       Impact factor: 17.367

7.  Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.

Authors:  Derek Leaderer; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  J Gene Med       Date:  2015 Jun-Jul       Impact factor: 4.565

Review 8.  Progress and prospects: immune responses to viral vectors.

Authors:  S Nayak; R W Herzog
Journal:  Gene Ther       Date:  2009-11-12       Impact factor: 5.250

9.  AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement.

Authors:  Xiaolei Pei; Ting He; Nikita E Hall; David Gerber; R Jude Samulski; Chengwen Li
Journal:  Virology       Date:  2018-02-16       Impact factor: 3.616

10.  Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1.

Authors:  Declan Madsen; Emma R Cantwell; Timothy O'Brien; Patricia A Johnson; Bernard P Mahon
Journal:  J Gen Virol       Date:  2009-07-29       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.